Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
+1 more
Sigma-1 receptor agonistketamine, MXE, DMXE +5 moreketamine, MXE, DMXE, MXPr, DCK, PCP, DXM, nitrous oxide show less
MXiPr
MXiPr (methoxisopropamine) is a synthetic dissociative of the arylcyclohexylamine class. It is the N-isopropyl variant of methoxetamine (MXE) — a compound once widely used as a ketamine alternative. It blocks glutamate signaling in the brain,[1] producing the characteristic dissociative state.
MXiPr (methoxisopropamine) is an emerging synthetic dissociative of the arylcyclohexylamine class. It is the N-isopropyl homolog of methoxetamine (MXE), distinguished by a longer afterglow and biphasic stimulant-to-sedative arc. MXiPr is an NMDA receptor antagonist, producing its effects by blocking glutamate-driven excitatory signaling in the brain.[1]
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
+1 more
Sigma-1 receptor agonistketamine, MXE, DMXE +5 moreketamine, MXE, DMXE, MXPr, DCK, PCP, DXM, nitrous oxide show less
MXiPr appeared on research chemical markets in late 2020, first formally identified by Slovenian forensic chemists that December.[2][3] It was designed to sidestep the legal controls placed on MXE after that compound was scheduled in multiple countries.[4][5] It continues to circulate in European markets, including in pressed tablet form where its identity may not be apparent to the user.[6]
Subjective effects include stimulation, bodily lightness, euphoria, dissociation, and a warm afterglow.[7] The experience unfolds in two phases — energizing lucidity giving way to deepening sensory disconnection, capped by warmth that can linger for hours. Prolonged body load lasting up to two days, nausea, and compulsive redosing are common unwanted effects.
MXiPr carries moderate dependence potential, and no lethal dose has been established in any species. The greatest danger is combining it with CNS depressants — opioids, alcohol, or benzodiazepines — which can suppress breathing to a fatal degree; every fatal case involving related compounds involved polydrug combinations.[8][9] Only two substance-specific peer-reviewed studies exist;[1][2] nearly everything known about MXiPr's safety is inferred from chemically related compounds.
History[edit]
Discovery
MXiPr appeared on online research chemical markets in late 2020 with no prior description in pharmaceutical or academic literature. The National Forensic Laboratory of Slovenia performed the first formal identification in December 2020.[2][3] It is the N-isopropyl variant of methoxetamine (MXE) — a small structural change that produces a legally distinct molecule while preserving the pharmacological core.
Forensic and pharmacological characterization
MXiPr emerged alongside MXPr and DMXE as part of a wave of MXE analogues designed to circumvent scheduling across multiple jurisdictions.[4][5] Tanaka et al. identified it in seized products in Japan,[2] and Irie et al. published the only pharmacological study, measuring its potency at blocking glutamate receptors and flagging it as a serious concern given its potency and unregulated availability.[1]
Market presence
MXiPr continues to circulate in European drug markets. A harm reduction drug-checking service in Marseille detected it in a submitted pill in October 2024,[6] and the French Addictovigilance Network has flagged it in reports on emerging ketamine analogue use patterns.[10] Its detection in tablet form means it may be sold as or mixed with other substances.
The name methoxisopropamine follows NPS naming convention: "methox-" for the 3-methoxyphenyl group, "iso" for isopropyl, and "-amine." The abbreviation MXiPr mirrors siblings MXPr (N-propyl) and MXE (N-ethyl), with the lowercase "i" marking the isopropyl branch. The alternate form MXiP also appears in community contexts. Among dissociative users, MXiPr is sometimes framed as a successor to MXE — a compound that achieved near-mythical status after widespread international scheduling made it increasingly scarce.
Chemistry[edit]
Structural class
MXiPr belongs to the arylcyclohexylamine family — compounds built around a cyclohexane ring joined to an aromatic group and an amine. This scaffold is shared with ketamine, PCP, and methoxetamine (MXE). MXiPr is the N-isopropyl homolog of MXE, with molecular formula C₁₆H₂₃NO₂ and a molecular weight of 261.365 g/mol — the same core molecule with a branched isopropyl group on the nitrogen instead of MXE's ethyl group.
Stereochemistry
MXiPr has two mirror-image forms (R and S enantiomers), separable in the laboratory.[11] Whether one form is more potent than the other has not been studied; for reference, S-ketamine is roughly twice as potent as R-ketamine at the same receptor target.[12]
Pharmacology[edit]
Mechanism of action
MXiPr blocks glutamate signaling in the brain by entering and plugging the ion channel used by NMDA receptors.[12][4] This is the same mechanism as ketamine and PCP. Reducing glutamate activity disrupts normal sensory processing and produces the dissociative state.
The only published potency measurement places MXiPr between MXE and DMXE in blocking strength.[1] MXE is known to also affect serotonin pathways,[13] but whether MXiPr shares that secondary activity is unknown. inferred
Pharmacokinetics
No human pharmacokinetic data exist for MXiPr. A study using rat tissue and human liver cells identified the main metabolic pathways as breakdown of the isopropyl group, ring hydroxylation, and phase II conjugation[14] — the resulting metabolites can be detected in urine. People with liver impairment may experience longer drug exposure and greater toxicity risk, as established for the arylcyclohexylamine class.[12] inferred
Neuroscience[edit]
Where it acts
NMDA blockade disrupts communication between the thalamus and cortex — the pathway that stitches sensory information into coherent experience.[12] At lower doses, this selectively quiets inhibitory neurons, paradoxically increasing glutamate activity in the frontal brain and producing the stimulant-like lucidity reported at sub-dissociative amounts.[7] At higher doses, more complete blockade progressively disconnects the brain from sensory input, producing immersive disconnection.
Why it matters
By disrupting the brain's error-correction signaling at these synapses, these compounds degrade the internal model of reality — at low doses perception distorts; at high doses the model collapses. Separately, ketamine research has shown new neural connections can form rapidly following this type of receptor blockade[12] — whether MXiPr produces the same neuroplastic changes is unknown.
The O-desmethyl metabolite of MXE is substantially more potent at NMDA receptors than its parent compound[1] — does an analogous MXiPr metabolite contribute to or extend its effects? The prolonged aftereffects lasting up to 48 hours reported by users could reflect slow elimination, sustained receptor-level changes, or neuroplastic aftereffects — no pharmacokinetic data exist to distinguish these possibilities. Whether the R and S enantiomers differ in potency or safety, as they do for ketamine, also remains untested.
Subjective Effects[edit]
MXiPr's defining quality is its two-part arc — a stimulating, lucid opening that deepens into sensory disconnection, followed by a warm euphoric afterglow.[7] This arc is uncommon among arylcyclohexylamines and is frequently cited as what draws users back.
Within its class, MXiPr reads as more stimulating and less sedating than ketamine at comparable dissociative depths, with a longer and more pronounced afterglow than MXE. The overall character sits between the functional lucidity of low-dose ketamine and the deeper, enveloping warmth that MXE was known for.
MXiPr first appeared on research chemical markets in late 2020 and was formally identified by Slovenian forensic chemists that December.[2][3] It emerged alongside several MXE analogues designed to circumvent the scheduling of their parent compound across multiple jurisdictions.[4][5] It continues to circulate in European drug markets, including in pressed tablet form that complicates identification.[6]
Subjective effects include stimulation, bodily lightness, dissociation, and euphoric afterglow. The experience is defined by a biphasic arc — lucid, energizing dissociation at lower doses giving way to immersive disconnection at higher ones, capped by a warm afterglow that can persist for hours.[7] Prolonged body load lasting up to two days, nausea, and compulsive redosing are common unsought effects.
MXiPr carries moderate dependence potential, and no lethal dose has been established in any species. The primary risk is one of near-total ignorance — no controlled toxicity studies exist, and fatal cases involving closely related arylcyclohexylamines have involved polydrug combinations with CNS depressants.[8][9] Only two peer-reviewed studies provide substance-specific data;[1][2] nearly everything known about MXiPr's safety is inferred from its chemical relatives.
History[edit]
Discovery
MXiPr first appeared on online research chemical markets in late 2020, without any prior description in pharmaceutical or academic literature. The National Forensic Laboratory of Slovenia performed the first formal laboratory identification in December 2020.[2][3] Structurally, MXiPr is the N-isopropyl homolog of methoxetamine (MXE) — a minor modification to the nitrogen-attached alkyl chain that preserves the pharmacological core while producing a legally distinct molecule.
Forensic and pharmacological characterization
MXiPr emerged as part of a wave of MXE analogues — including MXPr and DMXE — designed to circumvent the scheduling of MXE across multiple jurisdictions.[4][5] Tanaka et al. reported MXiPr in seized products in Japan, representing the first published forensic identification.[2] Irie et al. subsequently published the only pharmacological characterization, measuring NMDA potency and flagging MXiPr as a "serious concern" given its potency and unregulated availability.[1]
Market presence
MXiPr continues to circulate in European drug markets. A harm reduction drug-checking service in Marseille detected MXiPr in a submitted pill in October 2024.[6] The French Addictovigilance Network has flagged the compound in the context of emerging ketamine analogue use patterns.[10] Its detection in tablet form indicates it may be substituted for or combined with other substances in pressed pills, complicating identification for end users.
The name methoxisopropamine follows NPS nomenclature convention: a portmanteau of "methox-" (3-methoxyphenyl), "iso" (isopropyl), and "-amine." The abbreviation MXiPr parallels the naming of its siblings MXPr (N-propyl) and MXE (N-ethyl), with the lowercase "i" denoting the isopropyl branch. The alternate abbreviation MXiP also circulates in community contexts. Within dissociative user communities, MXiPr is sometimes positioned as a successor to MXE — a compound that acquired near-mythical status after international scheduling made it increasingly scarce.
Chemistry[edit]
Structural class
MXiPr belongs to the arylcyclohexylamine chemical class — a family of compounds built around a cyclohexane ring bearing both an aromatic group and an amine nitrogen. This scaffold is shared with ketamine, phencyclidine (PCP), and methoxetamine (MXE). MXiPr is specifically a β-keto-arylcyclohexylamine, distinguished by a ketone group on the cyclohexane ring.
Within the MXE derivative series, MXiPr is the N-isopropyl homolog: the N-ethyl group of MXE is replaced with a branched isopropyl substituent. Closely related compounds include MXPr (N-propyl), DMXE (N-ethyl, lacking 3-methoxy), and deschloroketamine (DCK; N-methyl, lacking 3-methoxy).
Molecular identity
| Molecular formula | C₁₆H₂₃NO₂ |
| Molecular weight | 261.365 g/mol (free base) |
The molecular structure consists of a cyclohexanone ring bearing a 3-methoxyphenyl group and an isopropylamino substituent at the 2-position. The 3-methoxy group on the aromatic ring distinguishes MXiPr from deschloroketamine derivatives, while the N-isopropyl group differentiates it from MXE (N-ethyl) and MXPr (N-propyl). The compound is commercially available as the hydrochloride salt from analytical reference standard suppliers.
Stereochemistry
MXiPr possesses a chirality center at C2 of the cyclohexanone ring, producing two mirror-image enantiomers (R and S). Enantioseparation methods have been developed,[11] but no data comparing the potency or safety of R- versus S-MXiPr have been published. For reference, S-ketamine is approximately twice as potent as R-ketamine at NMDA receptors;[12] whether MXiPr exhibits comparable enantioselectivity is unknown.
Pharmacology[edit]
Mechanism of action
MXiPr acts primarily as an NMDA receptor antagonist — it enters the open ion channel of the NMDA and blocks it in a use-dependent manner, the same mechanism established for ketamine and PCP.[12][4] This blockade reduces glutamate-driven excitatory signaling, producing the characteristic dissociative state.
The only published measurement of MXiPr's receptor-level potency places it between MXE and DMXE in NMDA blocking strength.[1] An in silico docking study confirmed the compound interacts within the NMDA receptor channel pore.[1]
MXE has demonstrated affinity for the SERT (SERT)[13] and sigma receptors,[13] but whether MXiPr shares these secondary targets is unknown. The N-isopropyl substitution may alter binding at these sites relative to the N-ethyl parent. No published data exist for MXiPr at dopamine or norepinephrine transporters. inferred
Pharmacokinetics
No human pharmacokinetic studies have been published for MXiPr. Plasma half-life, bioavailability, and protein binding remain uncharacterized in humans.
The most detailed metabolic study examined MXiPr in rats and human liver microsomes.[14] The primary metabolic pathways identified were N-dealkylation (loss of the isopropyl group, yielding the nor-metabolite), hydroxylation on the aromatic or cyclohexane ring, and phase II conjugation including glucuronidation. These metabolites enable targeted urinary detection of MXiPr use.[14]
Arylcyclohexylamines are generally processed by the liver, as established for ketamine.[12] Individuals with impaired liver function may experience prolonged drug exposure and increased toxicity risk. inferred
Neuroscience[edit]
Where it acts
NMDA blockade by arylcyclohexylamines disrupts communication between the thalamus and cortex — the pathway responsible for integrating sensory information into coherent experience.[12] At lower doses, this preferentially silences inhibitory interneurons, paradoxically increasing glutamate release in prefrontal regions and producing the stimulant-like lucidity reported at sub-dissociative levels.[7] At higher doses, more complete NMDA blockade progressively disconnects the brain from sensory input, producing the immersive "hole" states described by users.
Why it matters
The predictive processing framework offers a unified account of dissociative phenomenology: by disrupting precision-weighted error signaling at NMDA synapses, these compounds degrade the brain's internal model of reality. At low doses, perception distorts and self-monitoring weakens; at high doses, the model collapses into complete sensory disconnection. Separately, ketamine research has demonstrated rapid formation of new neural connections following NMDA blockade — a mechanism underlying its antidepressant effects.[12] Whether MXiPr produces comparable neuroplastic changes is unknown.
The O-desmethyl metabolite of MXE is substantially more potent at NMDA receptors than its parent compound[1] — does an analogous MXiPr metabolite contribute to or extend its effects? The prolonged aftereffects lasting up to 48 hours reported by users could reflect slow elimination, sustained receptor-level changes, or neuroplastic aftereffects — no pharmacokinetic data exist to distinguish these possibilities. Whether the R and S enantiomers differ in potency or safety, as they do for ketamine, also remains untested.
Subjective Effects[edit]
MXiPr produces a biphasic dissociative experience uncommon among arylcyclohexylamines. Low-to-moderate doses deliver a stimulating, lucid state marked by bodily lightness and mood elevation; higher doses transition toward sedation and immersive disconnection, followed by a warm euphoric afterglow that persists for hours and is frequently cited as a driver of redosing.[7] Route of administration shapes the experience significantly — insufflation compresses the peak, while oral dosing extends duration and aftereffects.
Within its class, user reports position MXiPr as more stimulating and less sedating than ketamine at equivalent dissociative depths, with a longer and more pronounced afterglow than MXE. The overall character occupies a middle ground between the functional lucidity of low-dose ketamine and the deeper, enveloping warmth of MXE.
Effect Grid
Moderate dissociation with clearer bodily disconnection from the external environment. The stimulating quality transitions toward a more balanced state as dissociative depth increases. Music enhancement becomes prominent, and visual drifting and perspective distortion emerge as perceptual features.
Cognitive euphoria and conceptual thinking become apparent, alongside immersion enhancement. Time alteration is noticeable — subjective time perception may slow or become irregular. Motor control is noticeably impaired; walking and fine motor tasks require deliberate effort.
Pain suppression is well-established at this tier. Touch suppression develops alongside the deepening dissociation. The characteristic warm, euphoric quality of MXiPr's afterglow typically begins to manifest during the offset phase at this dose level.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Perspective distortion · Auditory distortion · Depth perception distortion · Vestibular distortion · Visual haze / noise · Visual drifting · Dreaming enhancement · Ganzfeld effect · Sensory deprivation · Sleep-transition hallucinations · Auditory enhancement · Auditory misinterpretation · Brightness alteration · Color alteration · Peripheral vision distortion · Tracers · Visual acuity suppression · Holotropic state · After-images · Auditory suppression · Color enhancement · Color suppression · Environmental patterning · Geometry · Light sensitivity · Olfactory suppression · Peripheral misidentification · Sound sensitivity · Synesthesia · Taste suppression · Tinnitus · Touch enhancement · Visual breathing · Visual magnification · Visual melting · Visual morphing · Visual acuity enhancement · Visual processing suppression · Internal hallucinations · Auditory hallucinations · External hallucinations · Environmental orbism / cubism · Object transformations · Perspective hallucinations · Visual scenery slicing · Visual recursion
Visual haze / noise · Visual drifting · Dreaming enhancement · Ganzfeld effect · Sensory deprivation · Sleep-transition hallucinations · Auditory enhancement · Auditory misinterpretation · Brightness alteration · Color alteration · Peripheral vision distortion · Tracers · Visual acuity suppression · Holotropic state · After-images · Auditory suppression · Color enhancement · Color suppression · Environmental patterning · Geometry · Light sensitivity · Olfactory suppression · Peripheral misidentification · Sound sensitivity · Synesthesia · Taste suppression · Tinnitus · Touch enhancement · Visual breathing · Visual magnification · Visual melting · Visual morphing · Visual acuity enhancement · Visual processing suppression · Internal hallucinations · Auditory hallucinations · External hallucinations · Environmental orbism / cubism · Object transformations · Perspective hallucinations · Visual scenery slicing · Visual recursion
Body schema distortion · Nystagmus (eye wobbles) · Sedation · Bodily lightness · Spontaneous body sensations · Muscle relaxation · Stimulation · Nausea · Bodily heaviness · Laughter fits · Nasal congestion · Physical fatigue · Pupil dilation · Tingling / electric sensations · Vibrations / buzzing · Excessive sweating · Appetite suppression · Bodily pressures · Breathing alteration · Dry mouth · Headache · Heart rate perception changes · Insomnia · Restlessness · Tactile euphoria · Wakefulness · Sexual arousal enhancement · Sexual arousal suppression · Abnormal heartbeat · Dehydration sensation · Involuntary body movements · Muscle tension · Trembling · Vasoconstriction · Vomiting · Watery eyes · Bodily dissociation · Seizure threshold reduction · Tactile hallucination · Phantom limb sensations
Bodily lightness · Spontaneous body sensations · Muscle relaxation · Stimulation · Nausea · Bodily heaviness · Laughter fits · Nasal congestion · Physical fatigue · Pupil dilation · Tingling / electric sensations · Vibrations / buzzing · Excessive sweating · Appetite suppression · Bodily pressures · Breathing alteration · Dry mouth · Headache · Heart rate perception changes · Insomnia · Restlessness · Tactile euphoria · Wakefulness · Sexual arousal enhancement · Sexual arousal suppression · Dehydration sensation · Involuntary body movements · Muscle tension · Trembling · Vasoconstriction · Vomiting · Watery eyes · Bodily dissociation · Seizure threshold reduction · Tactile hallucination · Phantom limb sensations
Thought disorganization · Memory suppression · Focus suppression · Information processing suppression · Memory fragmentation · Immersion enhancement · Thought deceleration · Aesthetic enhancement · Analysis suppression · Cognitive fatigue · Introspection enhancement · Thought loops · Humor enhancement · Pattern recognition suppression · Conceptual thinking · Compulsive redosing urge · Delusions of sobriety · Language suppression · Motivation suppression · Novelty enhancement · Openness enhancement · Creativity enhancement · Cognitive dysphoria · Cognitive flexibility · Humor suppression · Memory replays · Multiple thought streams · Thought acceleration · Thought connectivity · Amnesia · Delusions · Delirium
Information processing suppression · Memory fragmentation · Immersion enhancement · Thought deceleration · Aesthetic enhancement · Analysis suppression · Cognitive fatigue · Introspection enhancement · Thought loops · Humor enhancement · Pattern recognition suppression · Conceptual thinking · Delusions of sobriety · Language suppression · Motivation suppression · Novelty enhancement · Openness enhancement · Creativity enhancement · Cognitive dysphoria · Cognitive flexibility · Humor suppression · Memory replays · Multiple thought streams · Thought acceleration · Thought connectivity · Amnesia · Delusions · Delirium
Anxiety · Emotional enhancement · Empathy suppression · Anhedonia · Catharsis · Dysphoria · Emotional lability · Empathy enhancement · Irritability · Simultaneous emotions · Mania
Anhedonia · Catharsis · Dysphoria · Emotional lability · Empathy enhancement · Irritability · Simultaneous emotions
Disinhibition · Communication suppression · Sociability suppression · Automaticity · Craving · Emotional susceptibility · Social connection · Flow state · Sociability enhancement · Compulsive behavior reduction · Cognitive disconnection · Boundary dissolution · Identity alteration · Ego dissolution
Craving · Emotional susceptibility · Social connection · Flow state · Sociability enhancement · Compulsive behavior reduction · Cognitive disconnection · Boundary dissolution · Identity alteration · Ego dissolution
Time cessation
Death-rebirth sequence · Entity contact · Near-death experience · Non-dual awareness · Transpersonal feelings · Transpersonal memory access · Transpersonal visions
Transpersonal feelings · Transpersonal memory access · Transpersonal visions
Recursive awareness
Timeline
Gradual awareness shift over 20-60 minutes. Slower build than insufflation — the earliest signs are a subtle mood shift and mild bodily lightness.
Progressive dissociation and mood elevation develop steadily. Bodily lightness deepens, stimulation becomes noticeable, and perceptual softening begins.
Full effect plateau — broader and more sustained than the insufflated peak. Dissociative depth, cognitive euphoria, and music enhancement are at maximum intensity.
Slow tapering of effects. Dissociation recedes gradually and the warm afterglow emerges. Motor function and spatial orientation begin to normalize.
Extended warm residual state that may persist significantly — up to 48 hours in some individuals. Body load and cognitive softening may linger alongside mood elevation.
⚠ Do not drive or operate machinery for at least 12 hours after oral use.
Safety[edit]
- Acute toxicity
- Low
- Chronic toxicity
- Moderate
- Withdrawal
- Mild
- Tolerance buildup
- moderate
- Tolerance reset
- 10.5 days
- Physical
- Low
- Psychological
- Moderate
- Compulsive redosing
- Moderate
- Dose escalation
- Moderate
- Cross-tol.
- ketamine · MXE · DMXE
Toxicity
No controlled toxicity data exist for MXiPr. No lethal dose has been established in any species, and no human death attributed solely to MXiPr appears in published literature. safety citation needed
Deaths involving related compounds
Fatal cases involving structurally related arylcyclohexylamines provide the closest reference points. Deaths have been documented involving N-ethyldeschloroketamine,[8] 2-fluorodeschloroketamine,[9] and a combined 2F-DCK and 3-MeO-PCE intoxication.[15] In every case, high doses, polydrug use, and underlying health factors were involved.
Heart and circulation
Blocking glutamate signaling stimulates the sympathetic nervous system, raising heart rate and blood pressure.[12] No cardiovascular measurements specific to MXiPr have been published. inferred
Bladder and urinary tract
Chronic use of ketamine and MXE has been linked to bladder inflammation and scarring. Whether MXiPr carries the same risk is unknown — no clinical or animal data exist for this compound. inferred
Seizure risk
User reports describe seizures occurring at very high doses,[7] and compounds in this class can affect seizure threshold.[16] No published case reports confirm this for MXiPr specifically. safety citation needed
Prolonged body load
Users report body load persisting up to two days following even small doses[7] — longer than typically described for MXE or ketamine. The bulkier N-isopropyl group may slow liver metabolism, extending effective half-life, but no pharmacokinetic data confirm this.
Psychological risks
NMDA antagonists can cause anxiety, paranoia, and confusion during the acute phase, particularly at higher doses or in unfamiliar settings.[16] Working memory, decision-making, and spatial orientation are impaired during and shortly after use.
In vulnerable individuals, blocking glutamate signaling can trigger psychotic episodes — paranoia, hallucinations, and disordered thinking.[12] The antidepressant-like properties of NMDA antagonists may attract self-medication patterns, driving escalating use frequency.[12]
Tolerance & dependence
No published studies characterize MXiPr-specific tolerance or dependence. Tolerance builds as the brain compensates by upregulating glutamate activity; cross-tolerance with other dissociatives is expected,[16] with community estimates placing full reset around 1.5 weeks. inferred
Physical dependence potential is moderate, inferred from ketamine and MXE — withdrawal may bring anxiety, low mood, craving, and insomnia. Psychological dependence potential is also moderate; the warm afterglow[7] and antidepressant-like effects create meaningful reinforcement potential, and compulsive redosing has been noted in community reports.
Drug Interactions
No published interaction data exist for MXiPr. All assessments are class-level inferences from the arylcyclohexylamine profile. inferred
CNS depressants — opioids, benzodiazepines, alcohol, GHB, barbiturates — are the highest-risk combination. They stack on top of MXiPr's sedative effects and can suppress breathing to a fatal degree. A fatal case involving a related compound included co-presence of morphine, oxycodone, and venlafaxine.[8]
Serotonergic agents (MAOIs, SSRIs, SNRIs) may trigger serotonin syndrome — a life-threatening overheating and seizure response — if MXiPr shares the serotonin pathway affinity seen in MXE.[13] The fatal case reported by Theofel et al. involved co-administration with venlafaxine, an SNRI.[8]
Stimulants can mask sedation at higher doses, raising overdose risk, and add cardiovascular strain on top of the class-level increase in heart rate and blood pressure. Other dissociatives produce unpredictable amplification of effects through additive glutamate blockade — hazardous in individuals without tolerance.
Contraindications
8 knownNo substance-specific contraindication data exist for MXiPr. All are inferred from the arylcyclohexylamine class profile. inferred
Absolute contraindications:
- History of psychotic disorders: NMDA antagonists can trigger or worsen psychotic episodes. People with schizophrenia, schizoaffective disorder, or a personal history of psychosis should avoid all NMDA antagonists.
- Concurrent MAOI use: If MXiPr has serotonin pathway affinity (unconfirmed), combination with MAOIs poses serotonin syndrome risk.
Relative contraindications:
- Heart conditions: Raised heart rate and blood pressure pose elevated risk for people with pre-existing cardiovascular disease.
- Liver impairment: MXiPr undergoes extensive liver metabolism;[14] impaired function may prolong drug exposure and increase toxicity risk.
- Kidney or bladder conditions: Class-based concern for bladder and urinary tract damage, particularly with repeated use.
- Seizure disorders: User reports of seizures at high doses[7] and class-level seizure threshold effects[16] indicate elevated risk for people with epilepsy or a lowered seizure threshold.
- Pregnancy and breastfeeding: No reproductive toxicity data exist. NMDA signaling plays a critical role in developing brains; exposure during pregnancy carries theoretical risk to the developing nervous system. safety citation needed
Harm Reduction[edit]
Forms & Identification
MXiPr has been detected in pressed tablet form[6] — it may appear in pills without the user knowing what they contain. A substance sold as something else may contain MXiPr, or MXiPr purchased by name may contain something else entirely.
Reagent testing and quantitative drug-checking services (FTIR or GC-MS) are the only reliable ways to confirm identity and purity. Even confirmed MXiPr carries dosing uncertainty — no pharmacokinetic data exist to guide calibration. Start with the lowest reported active dose and adjust from there.
Guidelines
- Test every batch with reagent kits and, where available, quantitative drug-checking services
- Start with the lowest reported active dose, especially with a new batch or unfamiliar source
- Weigh doses with a milligram-precision scale — do not estimate by eye
- Allow full onset time before considering redosing (20–60 minutes oral; 5–15 minutes insufflated)
- Have a sober sitter present at moderate-to-high doses
- Keep the environment calm, familiar, and physically safe — remove tripping hazards and sharp objects
- Hydrate adequately but do not overdrink; keep water accessible
- Note that compulsive redosing has been reported — pre-measure doses and store the remainder out of reach
Set & Setting
MXiPr's biphasic profile means the appropriate environment shifts with dose. Lower amounts are manageable in social settings; moderate-to-high amounts require a safe, comfortable space with a trusted sitter present.
The prolonged aftereffects — body load potentially lasting two days — need to be factored into planning. Allow at least one full recovery day following use. Avoid driving, operating machinery, or making important decisions during the recovery window.
Aftercare & integration. MXiPr's prolonged body load — potentially lasting up to two days — means aftercare begins before the experience fully resolves. Prioritize sleep, light nutrition, and gentle physical activity during the recovery window. Avoid caffeine and stimulants, which may compound residual cardiovascular effects.
Dissociative experiences can produce lasting shifts in self-perception and worldview. If the experience was intense or unsettling, journaling within 24–48 hours can help process what occurred. If depersonalization or derealization persists beyond a few days, consult a mental health professional experienced with substance-related concerns.
Recovery & Support
The warm afterglow and antidepressant-like qualities reported for MXiPr may drive escalating use frequency, particularly in people self-medicating for depression or emotional distress. If use is becoming more frequent, requiring higher doses, or feeling compulsive, professional support would be beneficial.
Resources include addiction counseling services, harm reduction organizations, and peer support communities. SAMHSA's National Helpline (1-800-662-4357) provides free, confidential referrals in the United States.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency: Uncomfortable dissociation, mild nausea, and confusion are expected effects, not emergencies. Seek immediate help if any of the following occur: seizure activity, loss of consciousness, severely slowed or stopped breathing, chest pain, extreme agitation with self-harm risk, or complete unresponsiveness.
Immediate steps:
- 1. Call emergency services immediately if the person is unconscious, seizing, or not breathing normally.
- 2. Place an unconscious but breathing person in the recovery position (on their side, airway clear).
- 3. Do not leave the person alone.
- 4. Do not induce vomiting.
- 5. Do not physically restrain unless there is immediate danger of self-harm.
- 6. Monitor breathing continuously while waiting for help.
What to tell the dispatcher: Name the substance (MXiPr / methoxisopropamine — a dissociative), approximate amount taken, time of ingestion, current symptoms, and any other substances involved. Good Samaritan laws in many jurisdictions protect people who call for help during a drug emergency.
Legal Status[edit]
MXiPr has been explicitly scheduled in only a few countries. Elsewhere, structural analog laws may apply depending on how its structural relationship to controlled substances — particularly PCP and ketamine — is interpreted by prosecutors.
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States | Not federally scheduled | The Federal Analogue Act (21 U.S.C. § 813) may apply if intended for human consumption. Structural similarity to PCP (Schedule II) could support prosecution; ketamine is Schedule III, complicating analogue arguments. California lists MXiPr as Schedule I at the state level.citation needed |
| United Kingdom | Class B (Misuse of Drugs Act 1971) | Covered under the generic arylcyclohexylamine definition.[3] |
| Germany | NpSG | Controlled under the Neue-psychoaktive-Stoffe-Gesetz; permitted only for industrial or scientific purposes.[3] |
| Canada | Schedule I (CDSA) | Controlled under the Controlled Drugs and Substances Act.[3] |
| Hungary | Prohibited | Production, sale, and possession banned since April 2021.[3] |
| Japan | Controlled | Regulated under designated substances legislation; identified in illegal product seizures.[2] |
| Australia | Uncertain | Not confirmed as explicitly listed under the Poisons Standard (SUSMP). State and territory laws may cover MXiPr under analogue provisions.citation needed |
Legal status changes frequently and varies by jurisdiction. This information may not reflect current law. Nothing here constitutes legal advice.
Safety[edit]
- Acute toxicity
- Low
- Chronic toxicity
- Moderate
- Withdrawal
- Mild
- Tolerance buildup
- moderate
- Tolerance reset
- 10.5 days
- Physical
- Low
- Psychological
- Moderate
- Compulsive redosing
- Moderate
- Dose escalation
- Moderate
- Cross-tol.
- ketamine · MXE · DMXE
Toxicity
No controlled toxicity data exist for MXiPr. No lethal dose has been established in any species, and no human fatalities attributed solely to MXiPr appear in published literature. safety citation needed
Deaths involving related compounds
Fatal cases involving structurally related arylcyclohexylamines provide the closest available reference points. One death involving N-ethyldeschloroketamine (2-Oxo-PCE) was reported in a person who had also taken venlafaxine.[8] Two deaths involving 2-fluorodeschloroketamine (2-FDCK) have been documented.[9] A fatal intoxication involving 2F-DCK combined with 3-MeO-PCE has also been reported.[15] In every case, high doses, polydrug use, and underlying health factors were involved.
Heart and circulation
NMDA antagonists including ketamine produce dose-dependent increases in heart rate and blood pressure through stimulation of the sympathetic nervous system.[12] No cardiovascular measurements specific to MXiPr have been published. inferred
Bladder and urinary tract
Chronic ketamine and MXE use has been associated with bladder inflammation, scarring, and urinary symptoms. Whether MXiPr carries this risk is unknown — no clinical or animal data exist for this compound. inferred
Seizure risk
User reports describe seizures occurring at very high doses of MXiPr.[7] No published case reports confirm this for MXiPr specifically, though NMDA antagonists as a class can affect seizure threshold.[16] safety citation needed
Prolonged body load
Users report a body load persisting up to two days following even small doses of MXiPr — longer than typically described for MXE or ketamine.[7] One hypothesis is that the bulkier N-isopropyl group slows liver metabolism, resulting in a longer effective half-life, but no pharmacokinetic data confirm this.
Psychological risks
No published data characterize MXiPr's psychological risk profile specifically. Class-level risks for NMDA antagonists include anxiety, paranoia, and confusion during the acute phase — particularly at higher doses or in unfamiliar settings.[16]
Dose-dependent impairment of working memory, decision-making, and spatial orientation occurs during and shortly after use. NMDA antagonists can trigger psychotic episodes in vulnerable individuals — the glutamate model of psychosis identifies NMDA blockade as a mechanism for both substance-induced and endogenous psychotic states.[12]
Depersonalization and derealization are defining effects of the dissociative class, not adverse events per se, but may become distressing or persistent in susceptible individuals. The antidepressant-like properties observed for ketamine and MXE may attract self-medication use, creating patterns of escalating frequency.[12]
Tolerance & dependence
No published studies characterize MXiPr-specific tolerance or dependence.
Tolerance develops with repeated use of NMDA antagonists as the brain compensates by increasing its glutamate signaling capacity. Cross-tolerance within the dissociative class — all NMDA antagonists — is expected.[16] Community estimates place the functional tolerance half-life at approximately 5 days with full reset around 1.5 weeks. inferred
Physical dependence potential is moderate based on class inference from ketamine and MXE. Withdrawal from chronic NMDA antagonist use may involve anxiety, low mood, craving, and insomnia.
Psychological dependence potential is moderate. The warm, euphoric afterglow described in user reports,[7] combined with the antidepressant-like properties of NMDA antagonists, suggests meaningful reinforcement potential. Compulsive redosing has been noted in community reports.
Drug Interactions
No published drug interaction data exist for MXiPr. All assessments below are class-level inferences from the arylcyclohexylamine profile. inferred
CNS depressant combinations represent the highest-risk category. Additive depression of consciousness and breathing with opioids, benzodiazepines, alcohol, GHB, and barbiturates may be life-threatening. The fatal N-ethyldeschloroketamine case involved co-presence of morphine, oxycodone, and other compounds.[8]
Serotonergic agent combinations carry potential risk if MXiPr shares the SERT affinity demonstrated for MXE.[13] Combinations with MAOIs, SSRIs, or SNRIs could increase serotonin syndrome risk. The fatal case reported by Theofel et al. involved co-administration with venlafaxine (an SNRI).[8]
Stimulant combinations may mask MXiPr's sedative effects at higher doses, increasing the risk of accidental overdose. Additive strain on the heart and circulation is a concern given the class-level increase in heart rate and blood pressure.
Other dissociative combinations produce unpredictable increases in dissociative intensity through additive NMDA receptor blockade. The interaction is hazardous in individuals without tolerance.
Contraindications
8 knownNo substance-specific contraindication data exist for MXiPr. The following are inferred from the arylcyclohexylamine class profile. inferred
Absolute contraindications:
- History of psychotic disorders: NMDA antagonists can trigger or worsen psychotic episodes. Individuals with schizophrenia, schizoaffective disorder, or a personal history of psychosis should avoid all NMDA antagonists.
- Concurrent MAOI use: If MXiPr possesses serotonin transporter affinity (unconfirmed, inferred from MXE), combination with MAOIs poses serotonin syndrome risk.
Relative contraindications:
- Heart conditions: The sympathomimetic effects of NMDA antagonists (increased heart rate and blood pressure) pose elevated risk for individuals with pre-existing cardiovascular disease.
- Liver impairment: MXiPr undergoes extensive liver metabolism.[14] Impaired liver function may prolong drug exposure and increase toxicity risk.
- Kidney or bladder conditions: Class-based concern for bladder and urinary tract damage, particularly with repeated use.
- Seizure disorders: User reports of seizures at high doses[7] and the class-level seizure threshold effects[16] indicate increased risk for individuals with epilepsy or lowered seizure threshold.
- Pregnancy and breastfeeding: No reproductive toxicity data exist. NMDA receptor signaling plays critical roles in brain development; exposure during pregnancy carries theoretical risk to the developing nervous system. safety citation needed
Harm Reduction[edit]
Forms & Identification
MXiPr has been detected in pressed tablet form,[6] meaning it may appear in pill preparations where its identity is not disclosed. This makes reagent testing and drug-checking services especially important — a substance sold as one thing may contain MXiPr, or MXiPr purchased by name may contain something else entirely.
Quantitative analysis (such as FTIR or GC-MS through a drug-checking service) is the only reliable method of confirming identity and purity. The lack of established pharmacokinetic data means that even confirmed MXiPr samples carry dosing uncertainty — start with the lowest reported active dose and adjust from there.
Guidelines
- Test every batch with reagent kits and, where available, quantitative drug-checking services
- Start with the lowest reported active dose, especially with a new batch or unfamiliar source
- Weigh doses with a milligram-precision scale — do not estimate by eye
- Allow full onset time before considering redosing (20–60 minutes oral; 5–15 minutes insufflated)
- Have a sober sitter present at moderate-to-high doses
- Keep the environment calm, familiar, and physically safe — remove tripping hazards and sharp objects
- Hydrate adequately but do not overdrink; keep water accessible
- Note that compulsive redosing has been reported — pre-measure doses and store the remainder out of reach
Set & Setting
MXiPr's biphasic profile — stimulation at lower doses, deep dissociation at higher ones — means the appropriate environment shifts with dose. Lower doses are manageable in social settings; moderate-to-high doses require a safe, comfortable space with a trusted sitter present.
The compound's prolonged aftereffects (body load persisting up to two days) should be factored into scheduling. Plan for at least one full recovery day following use. Avoid driving, operating machinery, or making important decisions during the aftereffect window.
Aftercare & integration. MXiPr's prolonged body load — potentially lasting up to two days — means aftercare begins before the experience fully resolves. Prioritize sleep, light nutrition, and gentle physical activity during the recovery window. Avoid caffeine and stimulants, which may compound residual sympathomimetic effects.
Dissociative experiences can produce lasting shifts in self-perception and worldview. If the experience was intense or unsettling, journaling within 24–48 hours can help process and contextualize what occurred. If depersonalization or derealization persists beyond a few days, consult a mental health professional experienced with substance-related concerns.
Recovery & Support
The warm afterglow and antidepressant-like qualities reported for MXiPr may create a pattern of escalating use frequency, particularly in individuals self-medicating for depression or emotional distress. If use is becoming more frequent, requiring higher doses, or feeling compulsive, these are signs that professional support would be beneficial.
Resources for dissociative-related dependency include addiction counseling services, harm reduction organizations, and peer support communities. SAMHSA's National Helpline (1-800-662-4357) provides free, confidential referrals in the United States.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency: Uncomfortable dissociation, mild nausea, and confusion are expected effects, not emergencies. Seek immediate help if any of the following occur: seizure activity, loss of consciousness, severely slowed or stopped breathing, chest pain, extreme agitation with self-harm risk, or complete unresponsiveness.
Immediate steps:
- 1. Call emergency services immediately if the person is unconscious, seizing, or not breathing normally.
- 2. Place an unconscious but breathing person in the recovery position (on their side, airway clear).
- 3. Do not leave the person alone.
- 4. Do not induce vomiting.
- 5. Do not physically restrain unless there is immediate danger of self-harm.
- 6. Monitor breathing continuously while waiting for help.
What to tell the dispatcher: Name the substance (MXiPr / methoxisopropamine — a dissociative), approximate amount taken, time of ingestion, current symptoms, and any other substances involved. Good Samaritan laws in many jurisdictions protect people who call for help during a drug emergency.
Legal Status[edit]
MXiPr occupies an ambiguous legal position in most jurisdictions. As a novel psychoactive substance that emerged in late 2020, it has been explicitly scheduled or prohibited in only a small number of countries. Its structural relationship to both ketamine (a controlled medicine) and PCP (a prohibited substance) creates variable legal exposure depending on how structural analog laws are interpreted.
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States | Not federally scheduled | The Federal Analogue Act (21 U.S.C. § 813) may apply if intended for human consumption. Structural similarity to PCP (Schedule II) could support prosecution; ketamine is Schedule III, complicating analogue arguments. California lists MXiPr as Schedule I at the state level.citation needed |
| United Kingdom | Class B (Misuse of Drugs Act 1971) | Covered under the generic arylcyclohexylamine definition.[3] |
| Germany | NpSG | Controlled under the Neue-psychoaktive-Stoffe-Gesetz; permitted only for industrial or scientific purposes.[3] |
| Canada | Schedule I (CDSA) | Controlled under the Controlled Drugs and Substances Act.[3] |
| Hungary | Prohibited | Production, sale, and possession banned since April 2021.[3] |
| Japan | Controlled | Regulated under designated substances legislation; identified in illegal product seizures.[2] |
| Australia | Uncertain | Not confirmed as explicitly listed under the Poisons Standard (SUSMP). State and territory laws may cover MXiPr under analogue provisions.citation needed |
The US federal status warrants particular caution. While MXiPr is not specifically scheduled, the Federal Analogue Act's applicability depends on prosecutorial interpretation of structural similarity. MXiPr's relationship to both ketamine (Schedule III, outside the Act's automatic trigger) and PCP (Schedule II, within its scope) creates legal ambiguity untested in court for this specific compound. Possession or distribution in the United States carries non-trivial legal risk despite the absence of explicit scheduling.
Frequently asked questions
What is MXiPr?
MXiPr is a synthetic dissociative of the arylcyclohexylamine class, acting primarily as an NMDA receptor antagonist. First identified in 2020 as the N-isopropyl homologue of methoxetamine, it remains largely uncharacterized in published research.
How long does MXiPr last?
Total duration by route of administration — Insufflated: 1.5 – 4 hours; Oral: 2 – 5 hours. Ranges vary with dose and individual factors; see the duration table for onset, peak, and after-effect phases.
Where can I find dosage information for MXiPr?
Psychedex publishes a dosage table for MXiPr on this page covering these routes of administration: oral, insufflated. Dose values are presented only in that table, always alongside their route of administration.
What are dangerous combinations with MXiPr?
The highest-severity documented interactions for MXiPr: GHB, GBL (Lethal), Anticholinergics (Dangerous), Antihistamines (Dangerous), Antipsychotics (Dangerous), Benzodiazepines (Dangerous). See the interactions section for the full list with mechanisms and severity levels.
Is MXiPr addictive?
Psychedex records tolerance and dependence data rather than a yes/no rating. Recorded tolerance indicators for MXiPr: tolerance builds moderate; full reset takes 10.5 days; cross-tolerance develops with ketamine, MXE, DMXE, MXPr, DCK, PCP, DXM, nitrous oxide. See the article's dependence and safety sections for recorded dependence data.
experience reports
No experience reports yet. Be the first to contribute.
First-person accounts of subjective effects, timing, and outcomes — submitted for harm reduction.
references
- [1]
- [2]
- [3]
- [4] ^abcWallach J, Brandt SD (2018) 1,2-Diarylethylamine- and Ketamine-Based New Psychoactive Substances — Handbook of Experimental Pharmacology doi:10.1007/164_2018_148
- [5] ^abWallach J, Brandt SD (2018) Phencyclidine-Based New Psychoactive Substances — Handbook of Experimental Pharmacology doi:10.1007/164_2018_124
- [6]
references
- [1]
- [2]
- [3]
- [4] ^abcWallach J, Brandt SD (2018) 1,2-Diarylethylamine- and Ketamine-Based New Psychoactive Substances — Handbook of Experimental Pharmacology doi:10.1007/164_2018_148
- [5] ^abWallach J, Brandt SD (2018) Phencyclidine-Based New Psychoactive Substances — Handbook of Experimental Pharmacology doi:10.1007/164_2018_124
- [6]